ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418

Its studies are led by Avenzo Therapeutics.

Furthest: phase 2, since Jun 18, 20251 company-led study, 1 open or runningNext primary completion: Jun 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Avenzo Therapeutics11 open or runningphase 2since Jun 18, 2025Jun 18, 2025Jun 2030phase 2 · NCT07038343

Also a collaborator on its studies: DualityBio.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2025First study: phase 2 study in Lung NeoplasmsFirst studyNCT07038343 · 480 planned · United States, China

Ahead

  1. Jun 2030Primary completion: phase 2 study in Lung NeoplasmsNCT07038343

TargetBeta

EGFR →ERBB3 →read by rule
“An antibody-drug conjugate (ADC) composed of a bispecific antibody, with a fragment antigen binding (Fab) arm targeting the tumor associated antigen (TAA) human epidermal growth factor receptor (EGFR; HER1; ErbB1) with medium affinity connected via a knock-into-hole (KIH) Fc domain to a single chain”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
CS5007ruleCStone Pharmaceuticalsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07038343Lung Neoplasms · United States, China2RecruitingJun 2030480

How it is read

Names in the registry

  • “AVZO-1418”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.